Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass.
Reston, VA-Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth.
Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass. Designed specifically for ovarian cancers that are resistant to traditional therapies, the new radiopharmaceutical can be produced in 25 minutes at low cost, which leads to better efficiency compared with alternative methods. This research was presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.
Phase 1 clinical trial to test a new, potential method against cancer news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: The clinical trial is the first step toward the team s overall goal: Developing a platform that combines radiotherapy with immunotherapy, drugs that help a patient s own immune system fight off. view more
Credit: Creative commons via Pxhere
A potential new weapon against cancer is entering the first phase of clinical trials thanks to a collaboration between Spectrum Health, the Lansing-based company Niowave and Michigan State University.
MSU s Kurt Zinn, a professor of biomedical engineering, radiology and small animal clinical sciences, is leading the effort to validate an innovative radiotherapy as part of a safe, more effective and potentially less costly treatment for bladder cancer.